{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:07:51Z","timestamp":1771355271922,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Research Foundation\u2014Flanders","award":["12X9420N"],"award-info":[{"award-number":["12X9420N"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Posaconazole is an antifungal drug used for prophylaxis and treatment of invasive fungal infections. Severe influenza has been identified as a risk factor for invasive pulmonary aspergillosis in critically ill patients. In this population, extracorporeal membrane oxygenation (ECMO) is used as rescue therapy, although little is known about the pharmacokinetics (PK) of posaconazole during ECMO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the PK and target attainment of six patients treated with IV posaconazole under ECMO and to develop a population PK model that can be used to simulate the PTA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Critically ill patients treated with posaconazole and ECMO were included in this study. Plasma samples were collected at several timepoints within one dosing interval on two occasions: an early (Day 2\u20133) and a late (Day 4\u20137) sampling day. Daily trough concentrations were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median (IQR) AUC0\u201324, CL and Vd were 34.3 (28.3\u201337.7) mg\u00b7h\/L, 8.7 (8.0\u201310.6) L\/h and 389 (314\u2013740) L, if calculated with non-compartmental analysis based on the observed concentrations. All measured trough concentrations were \u22650.7\u2009mg\/L and 11\/16 were \u22651\u2009mg\/L, which are the haematological thresholds for prophylaxis and treatment of invasive aspergillosis, respectively. The targeted PTA (&amp;gt;90%) was attained for prophylaxis but not for treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ECMO does not appear to influence posaconazole exposure compared with haematology patients. However, some trough levels were below the lower limit for treatment. An a priori dose adjustment does not appear to be necessary but drug monitoring is recommended.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab012","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T16:26:08Z","timestamp":1610555168000},"page":"1234-1241","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2103","authenticated-orcid":false,"given":"Ruth","family":"Van Daele","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and Pharmacy Department, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen and Center of Expertise in Mycology Radboudumc\/CWZ, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Ghent University Hospital, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Cotton","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, LHUB-ULB, Erasme Hospital and, Universit\u00e9 Libre de Bruxelles, Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fage","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, LHUB-ULB, Erasme Hospital and, Universit\u00e9 Libre de Bruxelles, Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-3772","authenticated-orcid":false,"given":"Matthias","family":"Gijsen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and Pharmacy Department, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenny","family":"Van Zwam","sequence":"additional","affiliation":[{"name":"Department of Perfusion, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, University Hospitals Leuven and Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, University Hospitals Leuven and Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and Pharmacy Department, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"2021041609051081000_dkab012-B1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2021041609051081000_dkab012-B2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2021041609051081000_dkab012-B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021041609051081000_dkab012-B4","author":"Lewis","year":"2015"},{"key":"2021041609051081000_dkab012-B5","first-page":"e1\u201338","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2021041609051081000_dkab012-B6","year":"2014"},{"key":"2021041609051081000_dkab012-B7","year":"2014"},{"key":"2021041609051081000_dkab012-B8","year":"2020"},{"key":"2021041609051081000_dkab012-B9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist Update"},{"key":"2021041609051081000_dkab012-B10","year":"2018"},{"key":"2021041609051081000_dkab012-B11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med"},{"key":"2021041609051081000_dkab012-B12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2021041609051081000_dkab012-B13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0000000000000504","article-title":"Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment","volume":"31","author":"Vanderbeke","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2021041609051081000_dkab012-B14","doi-asserted-by":"crossref","first-page":"741.e9\u201318","DOI":"10.1016\/j.jcrc.2012.02.013","article-title":"Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation","volume":"27","author":"Shekar","year":"2012","journal-title":"J Crit Care"},{"key":"2021041609051081000_dkab012-B15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","article-title":"Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment","volume":"33","author":"Mehta","year":"2007","journal-title":"Intensive Care Med"},{"key":"2021041609051081000_dkab012-B16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00134-008-1269-3","article-title":"Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation","volume":"35","author":"Ruiz","year":"2009","journal-title":"Intensive Care Med"},{"key":"2021041609051081000_dkab012-B17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021041609051081000_dkab012-B18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","article-title":"Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation","volume":"16","author":"Van Daele","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021041609051081000_dkab012-B19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13054-015-0891-z","article-title":"Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study","volume":"19","author":"Shekar","year":"2015","journal-title":"Crit Care"},{"key":"2021041609051081000_dkab012-B20"},{"key":"2021041609051081000_dkab012-B21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"Smith","year":"2012","journal-title":"Chest"},{"key":"2021041609051081000_dkab012-B22","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B23","doi-asserted-by":"crossref","first-page":"e00242-18","DOI":"10.1128\/AAC.00242-18","article-title":"Pharmacokinetics of intravenous posaconazole in critically ill patients","volume":"62","author":"Sime","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13054-019-2483-9","article-title":"Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients","volume":"23","author":"Sime","year":"2019","journal-title":"Crit Care"},{"key":"2021041609051081000_dkab012-B25"},{"key":"2021041609051081000_dkab012-B26"},{"key":"2021041609051081000_dkab012-B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2021041609051081000_dkab012-B28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/03007990903485056","article-title":"Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"26","author":"AbuTarif","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2021041609051081000_dkab012-B29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.01027-09","article-title":"Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation","volume":"54","author":"Kohl","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B30","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1128\/AAC.06167-11","article-title":"Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit","volume":"56","author":"Storzinger","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B31","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B32","doi-asserted-by":"crossref","first-page":"e01166-17","DOI":"10.1128\/AAC.01166-17","article-title":"Population pharmacokinetics of posaconazole tablets and Monte Carlo simulations to determine whether all patients should receive the same dose","volume":"61","author":"Petitcollin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B33","doi-asserted-by":"crossref","first-page":"e02465-17","DOI":"10.1128\/AAC.02465-17","article-title":"A population pharmacokinetic model for a solid oral tablet formulation of posaconazole","volume":"62","author":"van Iersel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-018-0658-1","article-title":"Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children","volume":"58","author":"Boonsathorn","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2021041609051081000_dkab012-B35","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021041609051081000_dkab012-B36","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.04223-14","article-title":"Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021041609051081000_dkab012-B37","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/jac\/dkw079","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021041609051081000_dkab012-B38"},{"key":"2021041609051081000_dkab012-B39","first-page":"288","article-title":"Medication adsorption into contemporary extracorporeal membrane oxygenator circuits","volume":"19","author":"Harthan","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2021041609051081000_dkab012-B40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13054-017-1644-y","article-title":"Medicating patients during extracorporeal membrane oxygenation: the evidence is building","volume":"21","author":"Dzierba","year":"2017","journal-title":"Crit Care"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1234\/37042370\/dkab012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1234\/37042370\/dkab012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T07:40:38Z","timestamp":1618645238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/5\/1234\/6124904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab012","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,1,29]]}}}